Table 2.

Effect of subunits on the interaction between open pore blockers and Kv channels.

α-Subunit	Ancillary subunit	Drug parameter modified by subunit
Kv1.5	Kvβ1.3	Decreases sensitivity to bupivicaine, quinidine and S0100176 (Gonzalez et al. 2002; Decher et al. 2005)
Kv4	KChIPs	Decreases sensitivity to nifedipine, nicardipine, bupivicaine and ropivicaine (Hatano et al. 2003; Friederich & Solth, 2004; Solth et al. 2005; Bett et al. 2006b).
		Slows development of block by ropivicane and bupivacaine (Friederich & Solth, 2004; Solth et al. 2005)
KCNQ1	KCNE1	Increases sensitivity to chromanol 293B, HMR 1556, S5557, azimilide, XE991 and 17 β-oestradiol (Busch et al. (Kv7.1) 1997; Wang et al. 2000; Schroeder et al. 2000; Lerche et al. 2000; Bett et al. 2006a).
		Affects use dependence (Seebohm et al. 2001; Bett et al. 2006a)
	KCNE2	Increases sensitivity to chromanol 293B (Tinel et al. 2000)
	KCNE3	Increases sensitivity to chromanol 293B, azimilide, XE991 and 17 β-oestradiol (Schroeder et al. 2000; MacVinish et al. 2001; Bett et al. 2006a)
HERG	KCNE2	Increases sensitivity to E4031 and propranolol (Abbott et al. 1999; Dupuis et al. 2005)
		(Kv11.1) Alters use dependence (Abbott et al. 1999)